NEJM.org
LightNews LightNews
banner
nejm.org
NEJM.org
@nejm.org
22K followers 260 following 1.6K posts
Welcome to the official Bluesky account for the New England Journal of Medicine. Follow for high-quality, peer-reviewed research and clinical content from the world’s leading medical journal, online at NEJM.org.

Follow @ai.nejm.org for medical AI content.
Posts Replies Media Videos
Pinned
nejm.org
NEJM.org @nejm.org · 18d
In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Full TARGET-FIRST trial results: nej.md/3UKJxS7

#MedSky
nejm.org
RC48-C016 phase 3 trial: For patients with HER2-expressing, locally advanced, or metastatic urothelial cancer, standard chemotherapy has limited benefit. Research findings on disitamab vedotin plus toripalimab are summarized in a Quick Take video. nej.md/48NBaMi

#MedSky #Oncology
A visual representation of the RC48-C016 trial, which evaluated disitamab vedotin plus toripalimab for patients with HER2-expressing, locally advanced or metastatic urothelial cancer.
December 15, 2025 at 8:01 PM
nejm.org
NEJM wants your lens on climate & health. Whether it’s Lyme in new zones, wildfire lung injury, or heat-related renal failure — submit high-quality clinical images for the April 2026 Climate Change and Health–themed Images in Clinical Medicine section. Learn more: nej.md/event-info
Call for Submissions Images Highlighting the Health Implications of Climate Change Submissions considered on a rolling basis through January 5, 2026. The NEJM identity sits at the bottom.
December 15, 2025 at 5:03 PM
nejm.org
In adults 65 to 79 years of age, there appeared to be fewer hospitalizations for influenza or pneumonia with high-dose influenza vaccine than with the standard dose, with a similar incidence of serious adverse events. Full GALFLU trial results and Research Summary: nej.md/46712T2 

#MedSky
The New England Journal of Medicine High-Dose Influenza Vaccine to Reduce Hospitalizations A Research Summary based on Pardo-Seco J et al. | 10.1056/NEJMoa2509834 | Published on August 30, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
December 15, 2025 at 2:02 PM
nejm.org
NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD, talks about a new study on using cap-refill time to manage resuscitation in septic shock. Read the full summary and see what else is new in this week's edition: nej.md/4s9tDQS

#CriticalCare
December 15, 2025 at 11:11 AM
nejm.org
Guidelines recommend dual antiplatelet therapy after CABG for acute coronary syndrome, but whether it reduces adverse events as compared with aspirin alone is unclear. Research findings from the TACSI trial are summarized in a new Quick Take video. nej.md/499wznZ

#MedSky #CardioSky
A visual representation of the TACSI trial, which assessed whether dual antiplatelet therapy after CABG for acute coronary syndrome reduces adverse events as compared with aspirin alone.
December 14, 2025 at 8:00 PM
nejm.org
A new study shows that aspirin enhances antimetastatic immunity by decreasing platelet activation, thereby releasing T cells from suppression by thromboxane A2. Learn more: nej.md/4pTzyaw

#MedSky @ucl.ac.uk
An illustrated diagram of the inhibition of platelet activation and the anticancer effects of aspirin.
December 14, 2025 at 5:00 PM
nejm.org
Among adults 65 years of age or older, a high-dose influenza vaccine did not result in a significantly lower incidence of hospitalization for influenza or pneumonia than a standard-dose vaccine. Full DANFLU-2 trial results and Research Summary: nej.md/4lPGMtT

#MedSky #IDSky
December 14, 2025 at 2:01 PM
nejm.org
The effectiveness of high-dose inactivated influenza vaccine at preventing hospitalization for influenza in adults 65 years of age and older is unclear. Research findings from the GALFLU trial are summarized in a new Quick Take video. nej.md/4535tgK

#MedSky #IDSky
A visual representation of the GALFLU trial, which compared the effectiveness of high-dose and standard-dose vaccine in preventing hospitalization for influenza in adults 65 years of age and older.
December 13, 2025 at 8:00 PM
nejm.org
Antibiotic duration for bacteremia is something most of us learned by habit, not by trial data. In the latest episode of Beyond Journal Club from @coreimpodcast.bsky.social and NEJM Group, we walk through the BALANCE trial and use it as a lens for treatment guidance. nej.md/3XNgajK
An illustration explaining the BALANCE trial
December 13, 2025 at 5:02 PM
nejm.org
An 80-year-old man presented to the emergency department with a 12-hour history of pleuritic chest pain and an elevated D-dimer level. A CT scan showed an ulcerlike projection in the ascending thoracic aorta. Read the full case details: nej.md/4pU0I1c

#MedSky
Images in Clinical Medicine Aortic Intramural Hematoma Panel A: A CT pulmonary angiogram at presentation Panel B: A follow-up CT angiogram of the chest Panel C: A photo of an intimal tear and dissection of the ascending aorta, in addition to the intramural hematoma
December 13, 2025 at 2:02 PM
nejm.org
A 72-year-old woman presented to the dermatology clinic with a 3.5-month history of an enlarging, painless lump on her left cheek. 1/2

#MedSky #DermSky
December 12, 2025 at 8:02 PM
nejm.org
In a new Perspective, Ziad Obermeyer, MD, writes that today, medical research builds up an understanding of the whole from molecular parts, but #ArtificialIntelligence can revive an approach building down from patient-level data to theory and understanding. Learn more: nej.md/4rWYakP
"Massive datasets of laboratory results and vital signs are pointing to mysterious 'set points' in individual patients’ physiology, with large implications for mortality." Perspective "Bedside to Bench — AI and the New Science of Medicine" by Ziad Obermeyer, M.D.
December 12, 2025 at 5:03 PM
nejm.org
Whether the high-dose influenza vaccine is more effective than the standard-dose vaccine in preventing severe outcomes of influenza in older adults is unclear. Research findings from the DANFLU-2 trial are summarized in a new Quick Take video. nej.md/3KVyVOZ

#MedSky #IDSky
A visual representation of a new trial that sought to determine whether the high-dose vaccine might also be superior in terms of preventing severe clinical outcomes of flu.
December 12, 2025 at 2:02 PM
nejm.org
In the latest episode of the Not Otherwise Specified podcast, host Lisa Rosenbaum, MD, and her guests dissect the common notion that the key to improving the primary care system is simply increasing reimbursement.

🎧 Full episode: nej.md/4oPVwKW

📄 Full episode transcript: nej.md/3KJLnBp
Not Otherwise Specified Episode 3.7 Raising a RUCkus
December 11, 2025 at 8:02 PM
nejm.org
Case Record of the MGH: A 5-year-old boy was admitted to the hospital because of fever and rash. Nonblanching papules spread from the feet to the legs, buttocks, lower back, arms, and ears. A diagnostic test was performed. Read the full case details: nej.md/4rV135I

#MedSky #DermSky
Case Records of the Massachusetts General Hospital A 5-Year-Old Boy with Fever and Rash Clinical photographs
December 11, 2025 at 5:01 PM
nejm.org
New in the December 11, 2025, issue of NEJM:

High-Dose Influenza Vaccine in Older Adults (DANFLU-2 trial) nej.md/4lPGMtT

High-Dose Influenza Vaccine and Hospitalizations (GALFLU trial) nej.md/46712T2
Images and descriptions of what's new on NEJM.org this week
December 11, 2025 at 2:02 PM
nejm.org
The authors of a new Perspective write that the market entry of generic liraglutide could meaningfully reduce the fiscal burden of GLP-1 drug coverage, but only if patients, clinicians, and insurers choose to leverage this opportunity. Read the full Perspective: nej.md/4oQyxPV

#MedSky
Perspective "The availability of a lower-cost generic GLP-1 agonist presents an opportunity to expand access to this drug class while mitigating the associated financial burden." "Generic Liraglutide — Overlooked but Not Forgotten" by Suhas Gondi, M.D., M.B.A., Aaron S. Kesselheim, M.D., J.D., M.P.H., and Benjamin N. Rome, M.D., M.P.H.
December 10, 2025 at 11:00 PM
nejm.org
A new review summarizes the diagnosis and treatment of complex regional pain syndrome, a rare limb-pain disorder. Early rehabilitation and multidisciplinary care are key; most patients improve within 18 months. Read the Clinical Practice article: nej.md/3MSMW0n

@liverpooluni.bsky.social #MedSky
Clinical Practice Complex Regional Pain Syndrome An illustration of the symptoms and signs of complex regional pain syndrome in the affected limb. The NEJM identity sits at the bottom.
December 10, 2025 at 10:40 PM
nejm.org
In 6 of 14 patients receiving immune checkpoint inhibitors, cell-free DNA methylation profiling revealed multiorgan damage with immune-related adverse events, often before symptoms appeared. Learn more: nej.md/4907cG5

#MedSky #Oncology #Immunology
A figure showing the presence or absence of organ damage after immune checkpoint inhibitor therapy.
December 10, 2025 at 10:25 PM
nejm.org
The authors of a new Perspective argue that the Trump administration’s agreements regarding glucagon-like peptide 1 receptor agonists could reduce prices and improve access for some patients — and lead to substantial additional spending. Learn more: nej.md/48JYdYf

#MedSky
Perspective "The agreements do not appear to include financial savings for privately insured Americans seeking to access these drugs using insurance." "Insurance Coverage and Pricing of Weight-Loss Drugs in the United States" by Stacie B. Dusetzina, Ph.D., and Rachel E. Sachs, J.D., M.P.H.
December 10, 2025 at 10:10 PM
nejm.org
A 66-year-old man presented with 2 weeks of shortness of breath and cough, 5 days of left flank pain, and 2 days of a rapidly expanding mass on his left side. Read the full case details: nej.md/3XwdW8i

#MedSky #PulmSky #IDSky
Images in Clinical Medicine Empyema Necessitans Panel A: A photo of the tender mass on the patient's lateral back on the left side. Panels B and C: Computed tomography of the chest (axial and coronal views).
December 10, 2025 at 9:03 PM
nejm.org
In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease. Full DESTINY-Breast05 phase 3 trial results: nej.md/4an3Az2
A figure showing invasive disease–free survival with trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1).
December 10, 2025 at 7:05 PM
nejm.org
A new review focuses on the idiopathic form of normal-pressure hydrocephalus, which develops late in life and without any known cause. It is also challenging to diagnose. Learn more: nej.md/4pxWVad
Key points from the Review Article "Idiopathic Normal-Pressure Hydrocephalus"
December 10, 2025 at 5:02 PM
nejm.org
A new trial of pegcetacoplan, a C3 and C3b inhibitor, in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis showed that the drug significantly reduced proteinuria. Full VALIANT phase 3 trial results and Research Summary: nej.md/4pmT67G

#MedSky
The New England Journal of Medicine Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN A Research Summary based on Fakhouri F et al. | 10.1056/NEJMoa2501510 | Published on December 4, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
December 10, 2025 at 2:42 PM
nejm.org
In a randomized trial involving critically ill patients undergoing intubation in EDs or ICUs, the use of ketamine for the induction of anesthesia did not lead to significantly lower in-hospital mortality than etomidate. Full trial results: nej.md/44EOlxB

@criticalcarereviews.com
CCR Down Under 2025 Original Article | Dec. 9, 2025 | NEJM.org Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults Figure 1. In-Hospital Death, According to Trial Group. The NEJM identity sits at the bottom.
December 10, 2025 at 12:20 AM